文献速递乳腺MRUS乳腺X线

对BRCA1或BRCA2突变女性采用每年两次自动乳腺超声、MR成像和乳腺X线摄影监测

Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
PubMed 文献 · Radiology · 2017-06-13

这项前瞻性多中心试验纳入296例BRCA突变携带者,评估每年全视野数字化乳腺X线摄影、动态增强MR成像联合每年两次自动乳腺超声的监测方案。BRCA突变携带者中自动乳腺超声未检出额外癌症,作者认为其可能对年度FFD乳腺X线摄影和DCE MR成像监测无附加价值;结果提示小于40岁的BRCA突变携带者可能无法从DCE MR成像之外的FFD乳腺X线摄影监测中获益。

要点

  • DCE MR成像敏感度68.1%(14/21),高于FFD乳腺X线摄影37.2%(8/21)和AB US 32.1%(7/21)。
  • AB US未检出额外癌症,作者认为其可能对年度FFD乳腺X线摄影和DCE MR成像监测无附加价值。
  • 小于43岁女性中FFD乳腺X线摄影未检出额外癌症,作者提示小于40岁者可能无法从FFD乳腺X线摄影监测中获益。

核心结论

  • AB US可能对BRCA突变携带者的年度FFD乳腺X线摄影和DCE MR成像监测无附加价值;结果提示小于40岁的BRCA突变携带者可能无法从DCE MR成像之外的FFD乳腺X线摄影监测中获益。

研究设计与样本

  • 前瞻性多中心试验,2010年9月至2012年11月纳入296例BRCA突变携带者(153例BRCA1、128例BRCA2及15例未检测的一级亲属),随访至2015年11月。

诊断标准与关键数值

  • DCE MR成像敏感度68.1%(14/21;95%CI:42.9%,85.8%),特异度95.0%(643/682;95%CI:92.7%,96.5%),癌检出率每100女性年2.0%(14/702),阳性预测值25.2%(14/54)。
  • FFD乳腺X线摄影敏感度37.2%(8/21;95%CI:19.8%,58.7%),特异度98.1%(638/652;95%CI:96.7%,98.9%),癌检出率每100女性年1.2%(8/671),阳性预测值33.7%(9/23)。
  • AB US敏感度32.1%(7/21;95%CI:16.1%,53.8%),特异度95.1%(1030/1088;95%CI:93.5%,96.3%),癌检出率每100女性年1.0%(7/711),阳性预测值9.5%(7/68)。
  • DCE MR成像联合FFD乳腺X线摄影敏感度最高为76.3%(16/21;95%CI:53.8%,89.9%),特异度93.6%(643/691;95%CI:91.3%,95.3%)。
  • BRCA2突变携带者中FFD乳腺X线摄影联合DCE MR成像监测敏感度为90.9%(10/11;95%CI:72.7%,100%),BRCA1突变携带者为60.0%(6/10;95%CI:30.0%,90.0%)。

临床应用与阅片要点

  • 筛查检出乳腺癌16例,年龄范围33-58岁;3例间期癌由自检发现,均为43岁以下BRCA1突变携带者。
  • 1例BRCA1突变携带者在对侧乳腺可触及异常处检出癌症;1例预防性乳房切除标本中偶然检出乳腺癌。
  • AB US未检出额外癌症;小于43岁(平均诊断年龄)女性中FFD乳腺X线摄影未检出额外癌症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate a multimodal surveillance regimen including yearly full-field digital (FFD) mammography, dynamic contrast agent-enhanced (DCE) magnetic resonance (MR) imaging, and biannual automated breast (AB) ultrasonography (US) in women with BRCA1 and BRCA2 mutations. Materials and Methods This prospective multicenter trial enrolled 296 carriers of the BRCA mutation (153 BRCA1 and 128 BRCA2 carriers, and 15 women with first-degree untested relatives) between September 2010 and November 2012, with follow-up until November 2015. Participants underwent 2 years of intensified surveillance including biannual AB US, and routine yearly DCE MR imaging and FFD mammography. The surveillance performance for each modality and possible combinations were determined. Results Breast cancer was screening-detected in 16 women (age range, 33-58 years). Three interval cancers were detected by self-examination, all in carriers of the BRCA1 mutation under age 43 years. One cancer was detected in a carrier of the BRCA1 mutation with a palpable abnormality in the contralateral breast. One incidental breast cancer was detected in a prophylactic mastectomy specimen. Respectively, sensitivity of DCE MR imaging, FFD mammography, and AB US was 68.1% (14 of 21; 95% confidence interval [CI]: 42.9%, 85.8%), 37.2% (eight of 21; 95% CI: 19.8%, 58.7%), and 32.1% (seven of 21; 95% CI: 16.1%, 53.8%); specificity was 95.0% (643 of 682; 95% CI: 92.7%, 96.5%), 98.1% (638 of 652; 95% CI: 96.7%, 98.9%), and 95.1% (1030 of 1088; 95% CI: 93.5%, 96.3%); cancer detection rate was 2.0% (14 of 702), 1.2% (eight of 671), and 1.0% (seven of 711) per 100 women-years; and positive predictive value was 25.2% (14 of 54), 33.7% (nine of 23), and 9.5% (seven of 68). DCE MR imaging and FFD mammography combined yielded the highest sensitivity of 76.3% (16 of 21; 95% CI: 53.8%, 89.9%) and specificity of 93.6% (643 of 691; 95% CI: 91.3%, 95.3%). AB US did not depict additional cancers. FFD mammography yielded no additional cancers in women younger than 43 years, the mean age at diagnosis. In carriers of the BRCA2 mutation, sensitivity of FFD mammography with DCE MR imaging surveillance was 90.9% (10 of 11; 95% CI: 72.7%, 100%) and 60.0% (six of 10; 95% CI: 30.0%, 90.0%) in carriers of the BRCA1 mutation because of the high interval cancer rate in carriers of the BRCA1 mutation. Conclusion AB US may not be of added value to yearly FFD mammography and DCE MR imaging surveillance of carriers of the BRCA mutation. Study results suggest that carriers of the BRCA mutation younger than 40 years may not benefit from FFD mammography surveillance in addition to DCE MR imaging. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. van Zelst JCM, Mus RDM, Woldringh G, et al. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography. Radiology. 2017. PMID: 28609204. doi:10.1148/radiol.2017161218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。